Substance Use Disorders Notable Among Adult Cancer Survivors

News
Article

Investigators indicate that ongoing efforts should focus on meeting the needs of adult cancer survivors with co-morbid substance use disorder, with an emphasis on prioritizing populations in which the disorder is highly present.

In a population of survivors who had received a diagnosis in the last 12 months, SUD was reported in 3.81%, and was highest in survivors of head and neck cancer (18.73%) and cervical cancer (15.70%). In this population, AUD (10.49%) was the most common SUD in survivors of cervical cancer along with OUD (4.82%). Moreover, the most common SUD among those with head and neck cancer was sedative use disorder (9.81%) and OUD (3.31%).

In a population of survivors who had received a diagnosis in the last 12 months, SUD was reported in 3.81%, and was highest in survivors of head and neck cancer (18.73%) and cervical cancer (15.70%). In this population, AUD (10.49%) was the most common SUD in survivors of cervical cancer along with OUD (4.82%). Moreover, the most common SUD among those with head and neck cancer was sedative use disorder (9.81%) and OUD (3.31%).

Substance use disorder (SUD) appears to be highly prevalent in survivors of certain types of cancer, with investigators indicating that it may be possible to identify survivors who might benefit from integrated cancer and SUD strategies, according to data from a study published in JAMA Oncology.1

Active SUD was reported in 3.83% of lifetime cancer survivors included in the study (n = 6101). Moreover, SUD occurred most frequently in survivors of head and neck cancers (9.36%), esophageal and gastric cancer (9.42%), cervical cancer (6.24%), and melanoma (6.20%). The most frequent SUD was alcohol use disorder (AUD; 2.78%) in the overall population as well as with survivors of head and neck cancer, cervical cancer, and melanoma.

“To our knowledge, this study presents the first population-based, cancer type–specific estimates of active SUD derived using gold-standard definitions,” the authors wrote. “Findings of this study highlight AUD as an important comorbidity affecting survivors of melanoma, cervical, and head and neck cancers. In these groups, AUD prevalence mirrors or exceeds that of health conditions known to commonly co-occur with cancer (eg, diabetes).”

Investigators used data from the annual National Survey on Drug Use and Health (NSDUH), which determines SUD prevalence in the last 12 months based on criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)—a known gold standard—and diagnostic interviews. One of the questions posed by the NSDUH concerns cancer history. Investigators included patients who were 18 years or older and who had a lifetime history of a solid malignancy. The survey included demographic data such as age, sex, race ethnicity, marital status, education level, annual income, insurance status, and disease type.

SUD was defined as meeting at least 1 of 4 DSM-IV criteria for abuse or 3 of 6 DSM-IV dependence criteria.2

In the main analytic cohort, 56.91% of patients were reported to 65 years of age or older and 61.63% were female. Additionally, most patients were non-Hispanic White (83.26%), married (60.60%), and were either college graduates (37.18%) or had a high school education or less (33.18%). The most common cancer types were breast cancer (26.05%), prostate and testicular cancer (15.66%), multiple cancers (18.19%), and melanoma (8.18%).

Investigators also reported that cannabis use disorder was the most common SUD in survivors of esophageal and gastric cancer (9.42%). Additionally, opioid and prescription sedative use disorders were found to be uncommon in those who survived all types of cancers. Conversely, head and neck cancer was considered to be an exception, with opioid use disorder (OUD) occurring in 1.40% and sedative use disorder occurring in 1.82%.

In a population of survivors who had received a diagnosis in the last 12 months, SUD was reported in 3.81%, and was highest in survivors of head and neck cancer (18.73%) and cervical cancer (15.70%). In this population, AUD (10.49%) was the most common SUD in survivors of cervical cancer along with OUD (4.82%). Moreover, the most common SUD among those with head and neck cancer was sedative use disorder (9.81%) and OUD (3.31%).

References

  1. Jones KF, Osazuwa-Peters O, Des Marais A, et al. Substance use disorders among US adult cancer survivors. JAMA Oncol. Published online January 11, 2024. doi:10.1001/jamaoncol.2023.5785
  2. Keyes KM, Rutherford C, Hamilton A, et al. What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size. Drug Alcohol Depend Rep. 2022;3: 100052. doi:10.1016/j.dadr.2022.100052
Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Related Content
Striving for Health Care Equity by Closing the Cancer Care Gap

Striving for Health Care Equity by Closing the Cancer Care Gap

April 18th 2024
Article

“If you were to ask me what the 1 magic thing would be, it would be that we would adopt a concept of 1 team, one fight nationally, and that we would be able to have our structures and our coordination of care.”

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Creating a First-of-Its-Kind Integrative Oncology Program at City of Hope

March 18th 2024
Podcast

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

FDA Grants Accelerated Approval to T-DXd in Advanced HER2+ Solid Tumors

April 5th 2024
Article

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Addressing Rising Cancer Incidence and Burden in Younger Populations

March 11th 2024
Podcast

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Updated ASCO Guideline Issues Vaccine Recommendations in Cancer Populations

March 31st 2024
Article

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.

FDA Clears IND for Novel Molecular Glue in Advanced Solid Tumors

March 29th 2024
Article

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.